Caputo Antonella, Castaldello Arianna, Brocca-Cofano Egidio, Voltan Rebecca, Bortolazzi Francesca, Altavilla Giuseppe, Sparnacci Katia, Laus Michele, Tondelli Luisa, Gavioli Riccardo, Ensoli Barbara
Department of Histology, University of Padova, Via A. Gabelli 63, 35122 Padova, Italy.
Vaccine. 2009 Jun 2;27(27):3605-15. doi: 10.1016/j.vaccine.2009.03.047. Epub 2009 Apr 7.
Anionic surfactant-free polymeric core-shell nanospheres and microspheres were previously described with an inner core constituted by poly(methylmethacrylate) (PMMA) and a highly hydrophilic outer shell composed of a hydrosoluble co-polymer (Eudragit L100-55). The outer shell is tightly linked to the core and bears carboxylic groups capable of adsorbing high amounts (antigen loading ability of up to 20%, w/w) of native basic proteins, mainly by electrostatic interactions, while preserving their activity. In the present study we have evaluated in mice the safety and immunogenicity of new vaccine formulations composed of these nano- and microspheres and the HIV-1 Tat protein. Vaccines were administered by different routes, including intramuscular, subcutaneous or intranasal and the results were compared to immunization with Tat alone or with Tat delivered with the alum adjuvant. The data demonstrate that the nano- and microspheres/Tat formulations are safe and induce robust and long-lasting cellular and humoral responses in mice after systemic and/or mucosal immunization. These delivery systems may have great potential for novel Tat protein-based vaccines against HIV-1 and hold promise for other protein-based vaccines.
先前已描述了无阴离子表面活性剂的聚合物核壳纳米球和微球,其内核由聚甲基丙烯酸甲酯(PMMA)构成,外壳高度亲水,由水溶性共聚物(Eudragit L100 - 55)组成。外壳与内核紧密相连,并带有羧基,这些羧基能够通过静电相互作用吸附大量(抗原负载能力高达20%,w/w)天然碱性蛋白质,同时保持其活性。在本研究中,我们在小鼠体内评估了由这些纳米球和微球与HIV - 1 Tat蛋白组成的新型疫苗制剂的安全性和免疫原性。疫苗通过不同途径给药,包括肌肉内、皮下或鼻内给药,并将结果与单独用Tat免疫或用明矾佐剂递送的Tat免疫的结果进行比较。数据表明,纳米球和微球/Tat制剂是安全的,并且在全身和/或粘膜免疫后能在小鼠体内诱导强烈且持久的细胞和体液反应。这些递送系统对于基于Tat蛋白的新型HIV - 1疫苗可能具有巨大潜力,并且有望用于其他基于蛋白的疫苗。